Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acrome… Read more
Crinetics Pharmaceuticals Inc (CRNX) - Total Assets
Latest total assets as of September 2025: $1.20 Billion USD
Based on the latest financial reports, Crinetics Pharmaceuticals Inc (CRNX) holds total assets worth $1.20 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Crinetics Pharmaceuticals Inc - Total Assets Trend (2016–2024)
This chart illustrates how Crinetics Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Crinetics Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Crinetics Pharmaceuticals Inc's total assets of $1.20 Billion consist of 95.9% current assets and 4.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.4% |
| Accounts Receivable | $8.47 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Crinetics Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Crinetics Pharmaceuticals Inc's current assets represent 95.9% of total assets in 2024, a decrease from 98.1% in 2016.
- Cash Position: Cash and equivalents constituted 18.4% of total assets in 2024, down from 96.5% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Crinetics Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Crinetics Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Crinetics Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Crinetics Pharmaceuticals Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Crinetics Pharmaceuticals Inc is currently not profitable relative to its asset base.
Crinetics Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.12 | 16.38 | 16.92 |
| Quick Ratio | 15.12 | 16.38 | 17.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.05 Billion | $ 824.02 Million | $ 167.00 Million |
Crinetics Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Crinetics Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.21 |
| Latest Market Cap to Assets Ratio | 2.27 |
| Asset Growth Rate (YoY) | 125.8% |
| Total Assets | $1.43 Billion |
| Market Capitalization | $3.26 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Crinetics Pharmaceuticals Inc's assets at a significant premium ( 2.27x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Crinetics Pharmaceuticals Inc's assets grew by 125.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Crinetics Pharmaceuticals Inc (2016–2024)
The table below shows the annual total assets of Crinetics Pharmaceuticals Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.43 Billion | +125.79% |
| 2023-12-31 | $635.35 Million | +80.41% |
| 2022-12-31 | $352.18 Million | +0.33% |
| 2021-12-31 | $351.01 Million | +91.35% |
| 2020-12-31 | $183.44 Million | +40.70% |
| 2019-12-31 | $130.38 Million | -23.94% |
| 2018-12-31 | $171.41 Million | +998.95% |
| 2017-12-31 | $15.60 Million | +23.80% |
| 2016-12-31 | $12.60 Million | -- |